TDNA
T. Rowe Price Biotech ETF
Price Chart
Latest Quote
$24.50
+0.63 (+2.63%)
Current Price
| Previous Close | $23.88 |
| Open | $24.47 |
| Day High | $24.50 |
| Day Low | $23.62 |
| Volume | 6,569 |
Fund Information
| Net Assets | $10.04M |
| Expense Ratio | 0.55% |
| Category | Health |
| Fund Family | T. Rowe Price |
| Net Asset Value | $23.93 |
| Premium/Discount | 2.39% |
| Exchange | NGM |
đ ETF Analysis
Company Data
Financial Ratios
Returns & Margins
Ownership
| Insider & Institutional transactions data not available |
Valuation Ratios
Analyst Data
Technical Indicators
| SMA20 | $23.97 |
| RSI | 54.87 |
| ATR | 0.5902 |
| Rel Volume | 3.30 |
Performance History
| Week | +0.75% |
| Month | -2.03% |
| YTD | -3.87% |
| 10 Years | -3.87% |
ETF Scoring Not Available
Exchange-traded funds (ETFs) are not scored using our fundamental analysis metrics, as they represent baskets of securities rather than individual companies.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $24.50 | 6,569 |
| 2026-10-26 | $23.90 | 4,200 |
| 2026-10-23 | $23.77 | 3,700 |
| 2026-10-22 | $24.11 | 500 |
| 2026-10-21 | $24.34 | 200 |
| 2026-10-20 | $24.32 | 300 |
| 2026-10-19 | $23.41 | 300 |
| 2026-10-16 | $22.72 | 600 |
| 2026-10-15 | $23.53 | 1,100 |
| 2026-10-14 | $23.06 | 700 |
| 2026-10-13 | $23.07 | 400 |
| 2026-10-12 | $23.88 | 10,200 |
| 2026-10-09 | $24.20 | 2,400 |
| 2026-10-08 | $23.57 | 1,100 |
| 2026-10-07 | $23.89 | 100 |
| 2026-10-06 | $24.01 | 1,000 |
| 2026-10-05 | $24.76 | 3,200 |
| 2026-10-02 | $24.57 | 100 |
| 2026-10-01 | $24.70 | 700 |
| 2026-09-30 | $25.14 | 2,500 |
| 2026-09-29 | $25.00 | 2,500 |
| 2026-09-28 | $25.01 | 1,500 |
About T. Rowe Price Biotech ETF
The fund normally invests at least 80% of its net assets (plus any borrowings for investment purposes) in the securities of biotechnology companies. It defines biotechnology companies as companies engaged in health care innovations, such as developing new and effective therapies to treat and cure disease through the use of living cells. The fund references the MSCI GICS (Global Industry Classification Standard) biotechnology and pharmaceuticals industries to identify such companies. The fund is non-diversified.
đ° Latest News
No news articles available at the moment. Check back later for updates on TDNA.
Period:
Loading...
No financial data available yet. Financial data will be fetched automatically.